Technological Barriers to Routine Genomic Surveillance for Vaccine Development Against SARS‐CoV‐2 in Africa: A Systematic Review
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.70047 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Kimberly Cheryl Chido Konono und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Global Health, University of Siena, Siena, SI, Italy. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, COVID-19 Vaccines, Genomics. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Global Initiative on Sharing All Influenza Data, a public‐access database for sharing severe acute respiratory syndrome coronavirus 2 genomic sequencing data, has received significantly less data from African countries compared to the global total. Furthermore, the contribution of these data was infrequent and, for some countries, non‐existent. The primary aim of this review is to identify the technological barriers to routine genomic surveillance in Africa. PubMed and Google Scholar were searched for the relevant articles, and other eligible articles were identified from the reference list examination according to the PRISMA checklist. Eighty‐four full‐text articles were analysed for eligibility, and 49 published full‐texted articles were included in the final qualitative analysis. The main technological barriers identified were limited genomic surveillance capacity, limited genomic sequencing infrastructure, lack of resources and skilled or trained scientists, and the high cost of importing, establishing, and maintaining a genomic sequencing facility. The Africa Pathogen Genomics Initiative aims to improve genomic surveillance capacity across Africa, through resources, training, education, infrastructure, and regional sequencing centres. Furthermore, collaborations between African governments and international partners or national, private, and academic institutions are imperative to sustain genomic surveillance in Africa, and investment in genomic sequencing and research and development is paramount. Longer turnaround times interfere with global viral evolution monitoring and national implementation of effective policies to reduce the burden and disease. Establishing effective genomic surveillance systems guides public health responses and vaccine development for diseases endemic in Africa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Global Health, University of Siena, Siena, SI, Italy.
- Global Clinical Development and Operations, BioNTech SE, Mainz, Germany.
- Clinical Operations, TRIFT Alliance Ltd, Kigali, Rwanda.
- National Microbiology Research Laboratory, Harare Central Hospital, Harare, Zimbabwe.
Zitieren
APA
Konono, K. C. C., Msusa, K., Mpinganjira, S., Amani, A., Nyagupe, C., & Ngigi, M. (2024). Technological Barriers to Routine Genomic Surveillance for Vaccine Development Against SARS‐CoV‐2 in Africa: A Systematic Review. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70047
Vancouver
Konono KCC, Msusa K, Mpinganjira S, Amani A, Nyagupe C, Ngigi M. Technological Barriers to Routine Genomic Surveillance for Vaccine Development Against SARS‐CoV‐2 in Africa: A Systematic Review. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.70047
BibTeX
@article{Konono2024,
author = {Konono, Kimberly Cheryl Chido and Msusa, Keiko and Mpinganjira, Samuel and Amani, Adidja and Nyagupe, Charles and Ngigi, Michael},
title = {Technological Barriers to Routine Genomic Surveillance for Vaccine Development Against SARS‐CoV‐2 in Africa: A Systematic Review},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.70047}
}
EUVIMED